APR Applied Pharma Research, Receives Notice of Allowance From USPTO For PKU GOLIKE

0 13

Relief Therapeutics Holding SA, a biopharmaceutical company focused on providing therapeutic relief to patients suffering from serious diseases with high unmet needs, announced today that its wholly-owned subsidiary, APR Applied Pharma Research SA (“APR”), has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for Patent Application No. 15/303,121, titled “Modified Release Orally Administered Amino Acid Formulations.”

The claims are for particular PKU GOLIKE formulations in APR’s product line that are meant to help patients with phenylketonuria manage their diets better (PKU). The PKU GOLIKE family of products is a phenylalanine-free food for special medical purposes (FSMP) made up of amino acid granules engineered with APR’s Physiomimic Technology, a modified-release amino acid technology that ensures prolonged physiological absorption while masking the amino acids’ unpleasant taste, odour, and aftertaste.

“The receipt of this Notice of Allowance from the USPTO for PKU GOLIKE®, powered by our proprietary, Physiomimic™ Technology, is another important milestone that helps strengthen our intellectual property position, which we will continue to build upon going forward. As we focus on increasing sales in the U.K. and Europe, we will continue our efforts in preparing for a potential U.S. launch. The novel formulation of each product within the PKU GOLIKE® family has proven to allow for the absorption of amino acids more closely resembling the natural protein in healthy humans, providing a distinct advantage for the treatment of patients suffering from PKU. As part of our commitment to expanding access to this important product, we are actively building out a U.S. commercial infrastructure, with the aim of launching PKU GOLIKE® as a treatment to PKU patients in the U.S. sometime in the second half of this year, assuming the product is approved for commercialization in the United States,”

stated Paolo Galfetti, Chief Executive Officer of APR and President of Relief Europe.

After determining that a patent should be awarded after any outstanding administrative criteria are met, the USPTO releases a patent Notice of Allowance. The patent issued as a result of this application will expire no earlier than September 27, 2036. The patent will be added to APR’s PKU GOLIKE intellectual property portfolio, which already includes U.S. Patent No. 10,500,180, which is set to expire on September 27, 2036.


Contact us with your feedback and suggestions.

Leave A Reply

Your email address will not be published.